Vaccine-induced seroconversion in participants in the North Carolina COVID-19 community Research Partnership.
Vaccine
; 40(42): 6133-6140, 2022 10 06.
Article
in English
| MEDLINE | ID: covidwho-2031731
ABSTRACT
Well-regulated clinical trials have shown FDA-approved COVID-19 vaccines to be immunogenic and highly efficacious. We evaluated seroconversion rates in adults reporting ≥ 1 dose of an mRNA COVID-19 vaccine in a cohort study of nearly 8000 adults residing in North Carolina to validate immunogenicity using a novel approach:
at-home, participant administered point-of-care testing. Overall, 91.4% had documented seroconversion within 75 days of first vaccination (median 31 days). Participants who were older and male participants were less likely to seroconvert (adults aged 41-65 adjusted hazard ratio [aHR] 0.69 [95% confidence interval (CI) 0.64, 0.73], adults aged 66-95 aHR 0.55 [95% CI 0.50, 0.60], compared to those 18-40; males aHR 0.92 [95% CI 0.87, 0.98], compared to females). Participants with evidence of prior infection were more likely to seroconvert than those without (aHR 1.50 [95% CI 1.19, 1.88]) and those receiving BNT162b2 were less likely to seroconvert compared to those receiving mRNA-1273 (aHR 0.84 [95% CI 0.79, 0.90]). Reporting at least one new symptom after first vaccination did not affect time to seroconversion, but participants reporting at least one new symptom after second vaccination were more likely to seroconvert (aHR 1.11 [95% CI 1.05, 1.17]). This data demonstrates the high community-level immunogenicity of COVID-19 vaccines, albeit with notable differences in older adults, and feasibility of using at-home, participant administered point-of-care testing for community cohort monitoring. Trial registration ClinicalTrials.gov NCT04342884.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Vaccines
/
COVID-19
Type of study:
Cohort study
/
Experimental Studies
/
Observational study
/
Prognostic study
/
Randomized controlled trials
Topics:
Vaccines
Limits:
Aged
/
Female
/
Humans
/
Male
Country/Region as subject:
North America
Language:
English
Journal:
Vaccine
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS